arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ARVINAS, INC.

ARVN
$8.74 ▲ +0.05 (+0.63%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
37 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
46
Health
Weak
Neutral
auto_awesome

Analytical Summary

ARVINAS, INC. shows mixed fundamentals. On the positive side, Debt to Equity remains strong. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $559.4M
Dividend Yield
Revenue Growth -91.7%
Op. Margin -409.0%
ROIC -16.5%
FCF / Share $-1.10
Trailing P/E
Price / Book 1.5x
FCF Yield
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Aug 7, 2026.

37-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$15.60M
↓ -91.7%
Net Income Profit after all expenses
$-57.60M
↑ +14.5%
Operating Margin Operating profit as % of sales
-409.0%
↓ -291.2% 5th
FCF / Share Free cash flow per share
$-1.10
↑ +10.6%
Long-Term Debt Long-term obligations
$500.00K
↓ -16.7%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
6
Returns
28
Financial Health
96
Cash Quality
93

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 37 quarters